Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Barclays PLC

Barclays PLC increased its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 127.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,668 shares of the company's stock after purchasing an additional 71,652 shares during the period. Barclays PLC owned 0.18% of Akero Therapeutics worth $3,662,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its position in shares of Akero Therapeutics by 54.4% during the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company's stock worth $226,554,000 after acquiring an additional 2,782,029 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Akero Therapeutics by 2.9% in the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company's stock valued at $203,053,000 after purchasing an additional 201,225 shares in the last quarter. RTW Investments LP boosted its holdings in Akero Therapeutics by 9.0% in the third quarter. RTW Investments LP now owns 5,919,435 shares of the company's stock valued at $169,829,000 after purchasing an additional 487,450 shares in the last quarter. Perceptive Advisors LLC increased its stake in Akero Therapeutics by 8.1% in the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company's stock valued at $35,188,000 after purchasing an additional 112,426 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in Akero Therapeutics during the third quarter worth approximately $37,392,000.

Akero Therapeutics Stock Performance

AKRO stock traded down $0.97 on Monday, hitting $28.37. The company's stock had a trading volume of 965,317 shares, compared to its average volume of 845,224. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -7.57 and a beta of -0.23. The firm has a 50 day moving average of $30.89 and a two-hundred day moving average of $27.54. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 1 year low of $15.32 and a 1 year high of $37.00.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.15). Equities analysts predict that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AKRO has been the subject of several research analyst reports. HC Wainwright restated a "buy" rating and issued a $50.00 target price on shares of Akero Therapeutics in a report on Monday, November 18th. Citigroup assumed coverage on shares of Akero Therapeutics in a research note on Monday, November 18th. They issued a "buy" rating and a $65.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Akero Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.83.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, insider Catriona Yale sold 9,061 shares of the company's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $27.73, for a total transaction of $251,261.53. Following the completion of the transaction, the insider now owns 74,158 shares in the company, valued at approximately $2,056,401.34. This represents a 10.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Cheng sold 108,366 shares of Akero Therapeutics stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $31.73, for a total transaction of $3,438,453.18. Following the completion of the sale, the chief executive officer now directly owns 605,417 shares in the company, valued at approximately $19,209,881.41. The trade was a 15.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 396,802 shares of company stock valued at $12,396,400 in the last ninety days. Insiders own 7.94% of the company's stock.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.